Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$35.7M Sell
320,576
-7,335
-2% -$868K 0.59% 60
2025
Q4
$44.2M Sell
327,911
-68,993
-17% -$7.53M 0.69% 51
2025
Q3
$33.7M Buy
+396,904
New +$24.3M 0.55% 68

Other funds holding ABVX

Eventide Asset Management's ABVX Position: Q1 2026 in Review

Eventide Asset Management reduced its Abivax (ABVX) stake by 2.2% in Q1 2026, selling an estimated $868K and leaving 320,576 shares worth $35.7M. The position accounts for 0.59% of the portfolio, ranked #60.

Eventide Asset Management first reported a position in ABVX in Q3 2025 and has held it in 3 quarters since. The position peaked at $44.2M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Eventide Asset Management held 320,576 shares of Abivax worth $35.7M as of Q1 2026.
  • Eventide Asset Management sold 7,335 Abivax shares in Q1 2026, an estimated $868K.
  • Abivax made up 0.59% of Eventide Asset Management's portfolio in Q1 2026, its #60 holding.
  • Eventide Asset Management first reported a position in Abivax in Q3 2025 and has held it in 3 quarters since.
  • Eventide Asset Management's Abivax position peaked at $44.2M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.